[HTML][HTML] uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
L Porcelli, M Guida, S De Summa… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Emerging evidence has highlighted the importance of extracellular vesicle (EV)-
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
[HTML][HTML] uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
L Porcelli, M Guida, S De Summa, R Di Fonte… - … for ImmunoTherapy of …, 2021 - jitc.bmj.com
Background Emerging evidence has highlighted the importance of extracellular vesicle (EV)-
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
[PDF][PDF] uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
L Porcelli, M Guida, S De Summa, R Di Fonte, I De Risi… - scholar.archive.org
Background Emerging evidence has highlighted the importance of extracellular vesicle (EV)-
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
L Porcelli, M Guida, S De Summa… - Journal for …, 2021 - search.proquest.com
Background Emerging evidence has highlighted the importance of extracellular vesicle (EV)-
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients.
L Porcelli, M Guida, S De Summa… - … for Immunotherapy of …, 2021 - europepmc.org
Background Emerging evidence has highlighted the importance of extracellular vesicle (EV)-
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
L Porcelli, M Guida, S De Summa… - Journal for …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Emerging evidence has highlighted the importance of extracellular vesicle (EV)-
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …
based biomarkers of resistance to immunotherapy with checkpoint inhibitors in metastatic …